Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

Journal of Clinical Pharmacology

Volumn 57, Issue 4, 2017, Pages 484-492

  Salem, Ahmed Hamed ^a,b   Agarwal, Suresh K ^a   Dunbar, Martin ^a   Enschede, Sari L Heitner ^a   Humerickhouse, Rod A ^a   Wong, Shekman L ^a  

^a ABBVIE INC   (United States)

^b Ain Shams University   (Egypt)

Author keywords

ABT 199 GDC 0199; BCL 2; CYP3A; food effect; pharmacokinetics; venetoclax

Indexed keywords

CYTOCHROME P450 3A INHIBITOR; VENETOCLAX; ANTINEOPLASTIC AGENT; FAT INTAKE; FUSED HETEROCYCLIC RINGS; PROTEIN BCL 2; SULFONAMIDE;

ACCUMULATION INDEX; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION AT STEADY-STATE; DIET RESTRICTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FOOD; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA RELAPSE; LIPID DIET; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; NONHODGKIN LYMPHOMA; ORAL CLEARANCE; PHARMACOKINETIC PARAMETERS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; URINE SAMPLING; ADMINISTRATION AND DOSAGE; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; DOSE RESPONSE; FAT INTAKE; FEMALE; FOOD DRUG INTERACTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; METABOLISM; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; COHORT STUDIES; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 85002931885     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.821     Document Type: Article

References (31)

1. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102:13944-13949.
2. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10:456–459.
3. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117:112–121.
4. Phillips DC, Xiao Y, Lam LT, et al. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5:e368. doi: 10.1038/bcj.2015.88.
5. Muqbil I, Mohammad RM. Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome. Ann Transl Med. 2015;3(20):312. doi: 10.3978/j.issn.2305-5839.2015.09.15.
6. Leverson JD, Phillips DC, Mitten MJ, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279ra40.
7. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488–496.
8. Seymour F, Roberts A, Carney DA, et al. Phase II study of navitoclax (ABT-263) safety and efficacy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): interim results. Haematologica. 2011;96(s2):227.
9. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
10. Vogler M, Dinsdale D, Dyer MJS, et al. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163(1):139–142.
11. Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013;54(8):1823–1825.
12. Roberts AW, Davids MS, Page JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
13. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–778.
14. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukaemia. Cancer Discov., 2016; Published OnlineFirst August 12. doi: 10.1158/2159-8290.CD-16-0313.
15. Moreau P, Chanan-Khan A, Roberts, AW, et al. Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results. Blood. 2105;126:3038.
16. De Vos S, Swinnen L, Kozloff M, et al. A dose-escalation study of venetoclax (ABT-199/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma. Blood. 2015;126:255.
17. DiNardo C, Pollyea D, Pratz K, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥65 years and not eligible for standard induction therapy. Blood. 2015;126:327.
18. United States Food and Drug Administration. Guidance for Industry. Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
19. Gerecitano JF, Roberts AW, Seymour JF, et al. A phase 1 study of venetoclax (ABT-199 / GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;126(23):254.
20. Jones AK, Freise KJ, Agarwal S, et al. Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin's lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 2016;18(5):1192–1202.
21. Michmerhuizen MJ, Lao Y, Wan K, et al. Absorption, metabolism and excretion of novel Bcl-2 inhibitor venetoclax in human [abstract]. Presented at: Great Lakes Drug Metabolism & Disposition Group Meeting; 2016, May 5-6; Rosemont, IL.
22. Venclexta (venetoclax) [US prescribing information]. North Chicago, IL; AbbVie Inc.; 2016.
23. Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet. 2004;43:1127–1156.
24. Choo EF, Boggs J, Zhu C, et al. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199. Drug Metab Dispos. 2014;42(2):207–212.
25. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60(6):702–716.
26. Porter CJ, Charman SA, Humberstone AJ, Charman WN. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. J Pharm Sci. 1996;85(4):357–361.
27. Khoo SM, Edwards GA, Porter CJ, Charman WN. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci. 2001;90(10):1599–1607.
28. Agarwal S, Salem AH, Danilov AV, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2016;Submitted.
29. Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study [published online ahead of print]. J Clin Pharmacol. 2016. doi: 10.1002/jcph.730.
30. Freise KJ, Jones AK, Eckert D, et al. Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia [published online ahead of print]. Clin Pharmacokin. 2016. doi: 10.1007/s40262-016-0453-9.
31. Salem AH, Agarwal S, Dunbar M, et al. Effect of low and high fat meals on the pharmacokinetics of venetoclax, a selective first-in-class Bcl-2 inhibitor [published online ahead of print]. J Clin Pharmacol. 2016. doi: 10.1002/jcph.741.